patent.fyi
Applications  /  US 2026/0355294
United States Patent Application Publication

US 2026/0355294 A1

Published
Nov 12, 2026
Filed
May 23, 2024
Earliest date on the face
May 23, 2023
Classification
A61K 38/4893
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Topical sodium channel blockade

What ifWhat if a lidocaine patch provides local pain relief?
Claim language“a botulinum toxin”

An adhesive backing holds a lidocaine-containing layer against intact skin over the painful area. Lidocaine blocks voltage-gated sodium channels in superficial sensory nerves and reduces ectopic firing in localized postherpetic neuralgia.

1.1Oral calcium channel modulation

What ifWhat if an oral gabapentin capsule treats the peripheral neuropathic pain?
Claim language“a botulinum toxin”

The capsule releases gabapentin in the gastrointestinal tract, where the drug is absorbed. Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels and reduces excitatory neurotransmitter release.

1.1Oral serotonin and norepinephrine modulation

What ifWhat if an oral duloxetine capsule treats painful diabetic polyneuropathy?
Claim language“a botulinum toxin”

An enteric coating protects the drug pellets in the stomach and releases them in the intestine. Duloxetine inhibits serotonin and norepinephrine reuptake and strengthens descending inhibition of pain signals.

1.2Surface delivery through intact skin

What ifWhat if a topical analgesic reaches superficial sensory nerves through intact skin?
Claim language“subcutaneously injected into a skin area”

A drug-loaded adhesive layer forms a continuous contact surface over the painful area. Lidocaine diffuses from the layer into the skin and reduces sodium channel activity in superficial sensory nerves.

1.2Metering by patch area

What ifWhat if the area of a topical analgesic patch determines the amount of drug loaded over the treatment site?
Claim language“a volume of 0.07 ml to 0.15 ml per injection point”

A manufactured lidocaine patch contains a specified mass of drug per unit area. The patch area and that areal loading determine the mass of lidocaine in the patch, which releases drug through its skin-contacting surface.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Injection mapping on a training phantom

A clinical training station uses a silicone skin sheet over a translucent gel layer. A printed overlay marks an irregular practice region and identifies the injection points within it. Trainees inject colored water into the gel and inspect the phantom from below to compare the deposits with the marked points.

Component substitution

Positive displacement pipette for phantom testing

A positive displacement pipette replaces the syringe in a bench fixture that dispenses dyed water into a transparent phantom. A rigid holder aligns the disposable pipette tip with preformed ports in the phantom. The operator lowers the tip to a mechanical stop, dispenses one aliquot, and moves the phantom to the next port.

Parameter or scale variation

Two spacing scales for phantom testing

A fixture holds two transparent gel coupons with identical surface materials. One coupon has 12 practice points spaced 8 mm apart, and the other has 12 points spaced 16 mm apart. A dispenser deposits dyed water at each point, and an overhead camera records the number of adjacent deposits that touch on each coupon.

Combination with existing systems

Pain mapping in an electronic record

An electronic clinical record includes a body map linked to the encounter note. The clinician draws the painful skin region as a polygon and records the side of the body, pain intensity, and examination date. The record displays successive outlines on the same body diagram so the clinician can compare changes in location and area.

Automated or data-driven variant

Camera verification of phantom deposits

An overhead camera images a transparent phantom after each dyed-water deposit. Software uses four corner markers to align each image with the phantom template and locates new dye by comparing consecutive frames. The software records the distance from each deposit center to its designated practice point and flags points with no detected deposit.

Pressure logging in a training fixture

An inline pressure sensor connects a water-filled dispenser to a transparent practice phantom. A data logger synchronizes the pressure trace with a plunger position sensor and stores each dispense cycle under the corresponding practice point. Software flags cycles that exceed a pressure threshold established from unobstructed runs on the same phantom.

Specific version of a part

Administration with vial identification

A clinician matches the patient record and medication order to the vial label before administration. The medication record captures the formulation, lot number, and administration date.

Administration with baseline pain scoring

A clinician records the patient's pain intensity on a numerical scale before administering the medication. The patient uses the same scale at follow-up to record pain intensity in the treated area.

Subcutaneous route recorded explicitly

The procedure record uses a dedicated field to record subcutaneous administration. A body diagram records the treated skin region and its laterality.

Injection points on a diagram

A skin diagram records individual injection locations relative to visible anatomical landmarks. Each mark corresponds to a point entry in the procedure record.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 7,691,983 B2
Published
Apr 6, 2010
Filed
Jan 14, 2005
Class
C07K 14/33
Document BUS 2012/0141532 A1
Published
Jun 7, 2012
Filed
Dec 12, 2007
Class
A61K 39/08
Claim 1
Document A
Document B
1.1administering a botulinum toxin to a patient
The patient is treated by a bolus injection of a modified neurotoxin subcutaneously to the shoulder; preferably the modified neurotoxin is botulinum type E comprising a leucine-based motif.
A · US 7,691,983 B2 · ¶ 114
Our invention also encompasses a method for treating a disease or condition in a human patient by administering to the patient a pharmaceutical composition comprising a botulinum neurotoxin and a viscous carrier for the botulinum neurotoxin, wherein the patient experiences significantly fewer complications due to the botulinum toxin than occur upon administration of a botulinum toxin formulation which does not comprise a viscous carrier.
B · US 2012/0141532 A1 · ¶ 38
1.2wherein the botulinum toxin is subcutaneously injected into a skin area of the patient at a concentration of 35 U/ml to 65 U/ml, and at a dose of 4.0 U to 6.0 U per injection point and a volume of 0.07 ml to 0.15 ml per injection point, and wherein the distance between injection points is 1.5 cm to 2.5 cm.
The patient is treated by a bolus injection of a modified neurotoxin subcutaneously to the shoulder; preferably the modified neurotoxin is botulinum type E comprising a leucine-based motif.
A · US 7,691,983 B2 · ¶ 114

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention relates to modified neurotoxins, particularly modified Clostridial neurotoxins, and use thereof to treat various conditions, including conditions that have been treated using naturally occurring botulinum toxins.
A · US 7,691,983 B2 · ¶ 2
It would be beneficial to have botulinum toxins with enhanced biological persistence and/or enhanced biological activity.
A · US 7,691,983 B2 · ¶ 4
In particular the present invention relates to an injectable botulinum toxin-hyaluronic acid formulation which can be administered with reduced local and systemic botulinum toxin induced complications.
B · US 2012/0141532 A1 · ¶ 2
The pharmaceutical compositions disclosed herein can have diagnostic, therapeutic, cosmetic and/or research utility.
B · US 2012/0141532 A1 · ¶ 3
Cite aspatent.fyi, US 2026/0355294 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355294/, SHA-256 3bd08ccddfa3405f960c771e922092e9e9c8e4f66027ebe8b7969cbe4b71c078
First published
Permanent addresshttps://patent.fyi/US20260355294/
Content fingerprint (SHA-256)3bd08ccddfa3405f960c771e922092e9e9c8e4f66027ebe8b7969cbe4b71c078
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi